Cohort 3 2.25 g ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
240フェニルケトン尿症1

240. フェニルケトン尿症


臨床試験数 : 138 薬物数 : 106 - (DrugBank : 11) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 5
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04256655
(ClinicalTrials.gov)
December 1, 202028/1/2020Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of CDX 6114 in PKU PatientsA Phase 1, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of CDX 6114 After Multiple Ascending Oral Dose Administration to Patients With Phenylketonuria (PKU).PhenylketonuriasDrug: cohort 1 0.225g;Drug: Cohort 2 0.75g;Drug: Cohort 3 2.25 gNestléNULLWithdrawn18 Years65 YearsAll0Phase 1NULL